Clinical trials: Lymphoma, Hodgkins
Non-Hodgkin Lymphoma
Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents
This is a diagnostic prospective multicenter study. This study will be conducted in 32 centers of the Société Française des Cancers et Leucémies de l'Enfants et de l'Adolescent (SCFE) in patients with non-Hodgkin lymphoma and…
- Trial name
- TEP-LYMPHOME (NCT02488369)
- Testing
- PET / CT
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Lymphoma
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous…
- Trial name
- NCT00061880
- Testing
- forodesine hydrochloride
- Where
- 3 sites in United States
- Sponsor
- BioCryst Pharmaceuticals
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma, Non-Hodgkin's, Adult
Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma
The purpose of this research is to help researchers find out if SP-3164 is safe and if it may be of benefit in the treatment of patients with Non-Hodgkin's lymphoma that has progressed after prior treatment, or that never…
- Trial name
- NCT05979857
- Testing
- SP-3164
- Volunteers
- 72 people
- Sponsor
- Salarius Pharmaceuticals, LLC
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Non Hodgkin's Lymphoma, Multiple Myeloma (MM)
Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
- Trial name
- NCT06720207
- Volunteers
- 30 people
- Sponsor
- Shanghai East Hospital
Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
- Trial name
- NCT06190067
- Testing
- Azacitidine Plus PD-1 therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Navy General Hospital, Beijing
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies.
- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome
- Trial name
- NCT05665530
- Testing
- PRT2527, Zanubrutinib, Venetoclax
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 86 people
- Sponsor
- Prelude Therapeutics Incorporated
Lymphoma Non-Hodgkin
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose…
- Trial name
- NCT02342665
- Testing
- Copanlisib (BAY80-6946)
- Where
- 13 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Bayer
AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT00310128
- Testing
- cisplatin, cytarabine, etoposide
- Sponsor
- AIDS Malignancy Consortium
Diffuse Large B-cell Lymphoma
Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma
This trial is a translational, prospective, open-label, monocentric research. The study will be conducted in a population of 60 patients with diffuse large B-cell lymphoma (DLBCL) for whom first-line treatment with R-CHOP is…
- Trial name
- SIMILY (NCT04696692)
- Testing
- Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Claudius Regaud
Solid Tumors, Non-Hodgkin Lymphoma
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, multicenter study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma.
- Trial name
- NCT03707093
- Testing
- ADG106
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Adagene Inc
Lymphoma, Non-Hodgkin
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
This is a single-arm, open-label, multicenter study of Iodine I-131 Anti B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for treatment of non-Hodgkin's lymphoma (NHL) who were previously treated with rituximab antibody.
- Trial name
- NCT00996593
- Testing
- Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
- Volunteers
- 43 people
- Sponsor
- GlaxoSmithKline
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients
The purpose of this study is to determine if FDA approved food safety guidelines are equivalent to a low bacterial diet (the neutropenic diet) with respect to the acquisition of infections during neutropenia in a sample of…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma, Sarcoma
- Trial name
- NCT00726934
- Testing
- Food Safety Guidelines, Neutropenic Diet
- Where
- 6 sites in United States
- Volunteers
- 149 people
- Sponsor
- Indiana University
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT07220993
- Testing
- CD7.CAR/28zeta T Cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Hodgkin Disease, Lymphoma, Large-cell, Anaplastic
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
- Trial name
- KLIO (NCT03942263)
- Where
- 50 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- Takeda
Recurrent Adult Hodgkin Lymphoma
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of temsirolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned or has not responded to treatment.
- Trial name
- NCT01902160
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL)
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the…
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM)
- Trial name
- NCT02920697
- Testing
- S 55746
- Where
- 18 sites in Australia, France and 6 more
- Volunteers
- 65 people
- Sponsor
- Institut de Recherches Internationales Servier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.